View Financial HealthProtagenic Therapeutics 배당 및 자사주 매입배당 기준 점검 0/6Protagenic Therapeutics 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Feb 19Protagenic Therapeutics, Inc. announced delayed 10-Q filingOn 02/18/2026, Protagenic Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Jan 16Nasdaq Stock Market to Delist Common Stock of Protagenic Therapeutics, IncThe Nasdaq Stock Market announced that it will delist the common stock, and warrants of Protagenic Therapeutics, Inc. Protagenic Therapeutics, Inc.’s securities were suspended on January 5, 2026 and have not traded on Nasdaq since that time.공시 • Jan 05Protagenic Therapeutics Receives Delisting Notice from NasdaqBeginning January 5, 2026, Protagenic Therapeutics, Inc. (the Company") expects its common stock (PTIX") and warrants (PTIXW") to be quoted for trading on the over-the-counter market. On December 31, 2025, the Company received a letter from The Nasdaq Stock Market LLC (Nasdaq") stating that trading of the Company's securities on Nasdaq would cease at the close of trading on January 2, 2026, and that Nasdaq determined to delist the Company's securities based on the Company's failure to satisfy Nasdaq continued listing requirements, including Nasdaq Listing Rule 5550(b)(1) (minimum stockholders' equity) and Nasdaq Listing Rule 5250(c)(1) (timely filing of periodic reports). OTC trading is effected through registered broker-dealers, and quotation and trading information is generally available through brokerage platforms and publicly available quotation services. The Company intends to continue to file periodic and current reports with the SEC, which will be available on the SEC's EDGAR system. The OTC market may have different liquidity and trading characteristics than a national securities exchange. The Company is evaluating steps to regain compliance with Nasdaq listing requirements and to seek relisting on Nasdaq. The Company also intends to engage with market participants to facilitate the OTC transition and support liquidity in its securities. The Company has withdrawn its request for a hearing before a Nasdaq Hearings Panel and, accordingly, Nasdaq's determination is final.공시 • Dec 08Protagenic Therapeutics, Inc., Annual General Meeting, Dec 31, 2025Protagenic Therapeutics, Inc., Annual General Meeting, Dec 31, 2025.공시 • Nov 27Protagenic Therapeutics, Inc. Receives Notification Letter from Nasdaq Delisting Due to Non-Compliance with Listing RulesOn November 20, 2025, Protagenic Therapeutics, Inc. received a notification letter (the “Notice”) from the Nasdaq Listing Qualifications Staff (the “Staff”) indicating that the Company is not in compliance with Nasdaq Listing Rule 5550(b)(1) (minimum stockholders’ equity of $2,500,000) and Nasdaq Listing Rule 5250(c)(1) (timely filing of periodic reports). As reported in the Company’s Transition Report on Form 10-QT for the period ended June 30, 2025, the Company’s stockholders’ equity no longer satisfies the minimum requirement of Rule 5550(b)(1). The Staff also cited the Company’s delated filing of its Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 as a separate basis for non-compliance under Rule 5250(c)(1). The Company is completing final steps for the Form 10-Q and expects to file it imminently. Because the Company had only recently regained compliance and remains subject to a mandatory one-year panel monitoring period under Nasdaq Listing Rule 5815(d)(4)(B), the Staff issued a determination to delist the Company’s securities from The Nasdaq Capital Market. The Company intends to timely request a hearing before a Nasdaq Hearings Panel (the “Panel”) to appeal the Staff’s determination. A timely hearing request will automatically stay any suspension of the Company’s securities for 15 calendar days. The Company will also request that the Panel a stay any suspension, pending the outcome of the hearing. During the automatic stay—and, if granted, during any extended stay—the Company’s common stock will continue to trade on The Nasdaq Capital Market. There can be no assurance that the Panel will grant the Company’s request for an extended stay or that the Company will regain compliance with Nasdaq’s continued listing standards.공시 • Nov 15Protagenic Therapeutics, Inc. announced delayed 10-Q filingOn 11/14/2025, Protagenic Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Aug 23Protagenic Therapeutics Receives Notice of Non-Compliance from Nasdaq Due to Delayed Filing of Form 10-QAs disclosed in the Company’s Form 12b-25 filed on August 14, 2025, Protagenic Therapeutics, Inc. is finalizing merger-related consolidation of financial statements for the quarter ended June 30, 2025, including purchase accounting adjustments, pro forma financial information, and related disclosures. These procedures are being completed under Audit Committee oversight with the Company’s independent auditors and external advisors. The Company expects to file its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 (the ‘Form 10-Q’) in the near future. On August 20, 2025, the Company received a notice (the ‘Notification Letter’) from the Nasdaq Listing Qualifications department (‘Nasdaq’) stating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) due to the delayed filing of the Form 10-Q. The notice does not immediately effect the listing or trading of the Company’s securities, which continue to trade on the Nasdaq Capital Market under the symbol ‘PTIX.’ The Company intends to submit a plan to regain compliance within 60 calendar days of the Notification Letter, and Nasdaq may grant an exception of up to 180 calendar days from the Form 10-Q’s due date.공시 • Aug 15Protagenic Therapeutics, Inc. announced delayed 10-Q filingOn 08/14/2025, Protagenic Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.New Risk • Aug 11New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$2.46m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Market cap is less than US$10m (US$2.46m market cap). Minor Risk Share price has been volatile over the past 3 months (16% average weekly change).지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 PTIX 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: PTIX 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Protagenic Therapeutics 배당 수익률 vs 시장PTIX의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (PTIX)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.2%업계 평균 (Biotechs)2.4%분석가 예측 (PTIX) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 PTIX 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 PTIX 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 PTIX 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: PTIX 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/26 23:20종가2026/05/26 00:00수익N/A연간 수익N/A데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Protagenic Therapeutics, Inc.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Feb 19Protagenic Therapeutics, Inc. announced delayed 10-Q filingOn 02/18/2026, Protagenic Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Jan 16Nasdaq Stock Market to Delist Common Stock of Protagenic Therapeutics, IncThe Nasdaq Stock Market announced that it will delist the common stock, and warrants of Protagenic Therapeutics, Inc. Protagenic Therapeutics, Inc.’s securities were suspended on January 5, 2026 and have not traded on Nasdaq since that time.
공시 • Jan 05Protagenic Therapeutics Receives Delisting Notice from NasdaqBeginning January 5, 2026, Protagenic Therapeutics, Inc. (the Company") expects its common stock (PTIX") and warrants (PTIXW") to be quoted for trading on the over-the-counter market. On December 31, 2025, the Company received a letter from The Nasdaq Stock Market LLC (Nasdaq") stating that trading of the Company's securities on Nasdaq would cease at the close of trading on January 2, 2026, and that Nasdaq determined to delist the Company's securities based on the Company's failure to satisfy Nasdaq continued listing requirements, including Nasdaq Listing Rule 5550(b)(1) (minimum stockholders' equity) and Nasdaq Listing Rule 5250(c)(1) (timely filing of periodic reports). OTC trading is effected through registered broker-dealers, and quotation and trading information is generally available through brokerage platforms and publicly available quotation services. The Company intends to continue to file periodic and current reports with the SEC, which will be available on the SEC's EDGAR system. The OTC market may have different liquidity and trading characteristics than a national securities exchange. The Company is evaluating steps to regain compliance with Nasdaq listing requirements and to seek relisting on Nasdaq. The Company also intends to engage with market participants to facilitate the OTC transition and support liquidity in its securities. The Company has withdrawn its request for a hearing before a Nasdaq Hearings Panel and, accordingly, Nasdaq's determination is final.
공시 • Dec 08Protagenic Therapeutics, Inc., Annual General Meeting, Dec 31, 2025Protagenic Therapeutics, Inc., Annual General Meeting, Dec 31, 2025.
공시 • Nov 27Protagenic Therapeutics, Inc. Receives Notification Letter from Nasdaq Delisting Due to Non-Compliance with Listing RulesOn November 20, 2025, Protagenic Therapeutics, Inc. received a notification letter (the “Notice”) from the Nasdaq Listing Qualifications Staff (the “Staff”) indicating that the Company is not in compliance with Nasdaq Listing Rule 5550(b)(1) (minimum stockholders’ equity of $2,500,000) and Nasdaq Listing Rule 5250(c)(1) (timely filing of periodic reports). As reported in the Company’s Transition Report on Form 10-QT for the period ended June 30, 2025, the Company’s stockholders’ equity no longer satisfies the minimum requirement of Rule 5550(b)(1). The Staff also cited the Company’s delated filing of its Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 as a separate basis for non-compliance under Rule 5250(c)(1). The Company is completing final steps for the Form 10-Q and expects to file it imminently. Because the Company had only recently regained compliance and remains subject to a mandatory one-year panel monitoring period under Nasdaq Listing Rule 5815(d)(4)(B), the Staff issued a determination to delist the Company’s securities from The Nasdaq Capital Market. The Company intends to timely request a hearing before a Nasdaq Hearings Panel (the “Panel”) to appeal the Staff’s determination. A timely hearing request will automatically stay any suspension of the Company’s securities for 15 calendar days. The Company will also request that the Panel a stay any suspension, pending the outcome of the hearing. During the automatic stay—and, if granted, during any extended stay—the Company’s common stock will continue to trade on The Nasdaq Capital Market. There can be no assurance that the Panel will grant the Company’s request for an extended stay or that the Company will regain compliance with Nasdaq’s continued listing standards.
공시 • Nov 15Protagenic Therapeutics, Inc. announced delayed 10-Q filingOn 11/14/2025, Protagenic Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Aug 23Protagenic Therapeutics Receives Notice of Non-Compliance from Nasdaq Due to Delayed Filing of Form 10-QAs disclosed in the Company’s Form 12b-25 filed on August 14, 2025, Protagenic Therapeutics, Inc. is finalizing merger-related consolidation of financial statements for the quarter ended June 30, 2025, including purchase accounting adjustments, pro forma financial information, and related disclosures. These procedures are being completed under Audit Committee oversight with the Company’s independent auditors and external advisors. The Company expects to file its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 (the ‘Form 10-Q’) in the near future. On August 20, 2025, the Company received a notice (the ‘Notification Letter’) from the Nasdaq Listing Qualifications department (‘Nasdaq’) stating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) due to the delayed filing of the Form 10-Q. The notice does not immediately effect the listing or trading of the Company’s securities, which continue to trade on the Nasdaq Capital Market under the symbol ‘PTIX.’ The Company intends to submit a plan to regain compliance within 60 calendar days of the Notification Letter, and Nasdaq may grant an exception of up to 180 calendar days from the Form 10-Q’s due date.
공시 • Aug 15Protagenic Therapeutics, Inc. announced delayed 10-Q filingOn 08/14/2025, Protagenic Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
New Risk • Aug 11New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$2.46m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Market cap is less than US$10m (US$2.46m market cap). Minor Risk Share price has been volatile over the past 3 months (16% average weekly change).